This suggests that apart from central actions, cyclophosphamide and its metabolites may act at the renal level, inducing NSIAD through V2R upregulation or direct effects, as demonstrated in animal studies [14,19,30,76]. Here, AVPR2 is linked to nephrogenic syndrome of inappropriate antidiuresis.